Q4 EPS Estimates for AngioDynamics Decreased by Analyst

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at HC Wainwright cut their Q4 2027 EPS estimates for shares of AngioDynamics in a research report issued to clients and investors on Wednesday, July 15th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.05. HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.26) per share.

ANGO has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics Trading Down 2.3%

NASDAQ:ANGO opened at $14.14 on Thursday. The company has a market capitalization of $584.41 million, a P/E ratio of -16.25 and a beta of 0.34. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $15.20. The firm has a fifty day simple moving average of $12.19 and a 200-day simple moving average of $11.34.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its position in AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after purchasing an additional 22,658 shares during the period. Jane Street Group LLC lifted its holdings in shares of AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after buying an additional 34,054 shares during the period. Legal & General Group Plc lifted its holdings in shares of AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 9,098 shares during the period. Rhumbline Advisers boosted its stake in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after buying an additional 2,510 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of AngioDynamics by 15.8% in the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after buying an additional 13,217 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics posted record fiscal Q4 and full-year results, with revenue growth, an earnings beat, and expanding gross margin, all of which support the bullish move in the stock. AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
• Positive Sentiment: The company raised its fiscal 2027 sales outlook, suggesting management sees continued momentum in demand and execution. AngioDynamics tops revenue forecasts and raises sales outlook for fiscal 2027 (ANGO)
• Neutral Sentiment: HC Wainwright raised its price target to $19 and kept a Buy rating, reinforcing the stock’s upside case even though the move also reflects that the shares have already appreciated meaningfully. HC Wainwright raised its price target on AngioDynamics
• Negative Sentiment: HC Wainwright also trimmed its Q4 2027 earnings estimate to $0.01 from $0.05, indicating analysts still see only modest near-term profit generation despite the improved outlook. AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.